The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse
Collectively, our findings uncover DNMT3B as a targetable vulnerability in high-risk patients with high DNMT3B/MYC levels.
Authors
- Eline Menu (ORCID: https://orcid.org/0000-0002-0805-6581)
- Lien Ann Van Hemelrijck (ORCID: https://orcid.org/0000-0002-7452-4283)
- Emma Verheye (ORCID: https://orcid.org/0000-0002-0731-8762)
- Karin Vanderkerken (ORCID: https://orcid.org/0000-0002-2137-7179)
- Arne Van der Vreken (ORCID: https://orcid.org/0000-0003-0345-721X)
- Jérôme Moreaux (ORCID: https://orcid.org/0000-0002-5717-3207)
- Elke De Bruyne (ORCID: https://orcid.org/0000-0003-4012-4617)
- Nathan De Beule (ORCID: https://orcid.org/0000-0002-8786-9168)
- Catharina Olsen (ORCID: https://orcid.org/0000-0002-6193-2296)
- Hatice Satilmis
- Robbe Heestermans (ORCID: https://orcid.org/0000-0003-2937-1705)
- Kim De Veirman (ORCID: https://orcid.org/0000-0002-1313-6121)
- Elina Alaterre (ORCID: https://orcid.org/0000-0003-4328-1191)
- Catharina Muylaert (ORCID: https://orcid.org/0000-0002-2347-9152)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université Libre de Bruxelles (BE)
- Vrije Universiteit Brussel (BE)
- Institut Universitaire de France (FR)
- Université de Montpellier (FR)
- Universitair Ziekenhuis Brussel (BE)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1186/s13046-025-03382-y
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- Multiple Myeloma Research Foundation
- Fonds Wetenschappelijk Onderzoek